← All trials
NCT03560271
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 18, 2018
- Primary completion
- Jun 30, 2019
- Completion date
- Jul 15, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 255
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NovMetaPharma Co., Ltd.Lead sponsor
- FGK Clinical Research GmbHCollaborator
- InClin, Inc.Collaborator
- NovMetaPharma Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.